Table 3. HRs (95% CIs) of fimasartan for clinical outcomes compared to other ARBs or valsartan.

Clinical outcomes of fimasartan		Number of cases	Incidence rate (per 1,000 person-years)	Unadjusted		Adjusted
				HR (95% CI)	P value	HR (95% CI)	P value
A composite outcomea		16	63.6
	Versus other ARBs			0.68 (0.37–1.24)	0.21	0.82 (0.46–1.45)	0.489
	Versus valsartan			0.74 (0.37–1.45)	0.36	0.84 (0.45–1.57)	0.593
All-cause death		6	22.4
	Versus other ARBs			0.50 (0.22–1.12)	0.09	0.70 (0.30–1.63)	0.412
	Versus valsartan			0.61 (0.25–1.49)	0.28	0.86 (0.32–2.28)	0.764
Recurrent myocardial infarction		5	19.4
	Versus other ARBs			1.30 (0.50–3.35)	0.59	1.28 (0.49–3.34)	0.614
	Versus valsartan			1.18 (0.44–3.19)	0.75	1.24 (0.43–3.61)	0.690
Hospitalization for heart failure		5	18.9
	Versus other ARBs			0.62 (0.21–1.79)	0.37	0.70 (0.27–1.84)	0.471
	Versus valsartan			0.58 (0.18–1.88)	0.36	0.61 (0.20–1.82)	0.373
Stroke		2	7.5
	Versus other ARBs			0.47 (0.13–1.61)	0.23	0.59 (0.18–1.96)	0.393
	Versus valsartan			0.46 (0.13–1.64)	0.23	0.49 (0.13–1.81)	0.278

HRs were adjusted for age, sex, previous revascularization, previous ARB or angiotensin-converting enzyme inhibitor therapy, diabetes mellitus, hypertension, hyperlipidemia, atrial fibrillation of flutter, chronic obstructive pulmonary disease, peripheral artery disease, malignancy, admission at tertiary hospital, and discharge medications.

ARB = angiotensin II receptor blocker, CI = confidence interval, HR = hazard ratio.

^aA composite of all-cause death, recurrent myocardial infarction, hospitalization for heart failure, and stroke.